Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention

被引：18
作者：
Garland, Scott G. [1 ,2 ]
Smith, Steven M. [1 ]
Gums, John G. [1 ]
机构：
[1] Univ Florida, Coll Pharm, Gainesville, FL USA
[2] Univ Florida, Coll Med, Gainesville, FL USA
来源：
ANNALS OF PHARMACOTHERAPY | 2019年 / 53卷 / 09期
关键词：
erenumab-aooe; erenumab; migraine; migraine prophylaxis; migraine prevention; chronic migraine; DOUBLE-BLIND; EPISODIC MIGRAINE; CONTROLLED-TRIAL; TOPIRAMATE; EFFICACY; SAFETY; PROPHYLAXIS; PREVALENCE; ADHERENCE; HEADACHE;
D O I：
10.1177/1060028019835166
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Objective: To review the pharmacology, efficacy, and safety of the calcitonin gene-related peptide (CGRP) inhibitor erenumab for migraine preventive therapy. Data Sources: A MEDLINE/PubMed search (January 2000 to January 2019) was conducted using the keywords erenumab-aooe, erenumab, migraine, migraine prophylaxis, migraine prevention, and chronic migraine. Additional articles were identified by hand from references. Study Selection and Data Extraction: We included English-language articles (excluding poster presentations) evaluating erenumab pharmacology, efficacy, or safety in humans for migraine prevention. Data Synthesis: Erenumab is a CGRP inhibitor that inhibits vasodilation in response to acute migraines, which decreases pain perception during the migraine. Erenumab efficacy and safety has only been compared with placebo, but its reduction in monthly migraine days (MMDs) and medication response (>= 50% reduction in MMDs) are comparable to current recommended off-label therapies for migraine prevention in short-term treatment studies. Additionally, erenumab is associated with low adverse event burden with no difference found compared with placebo per published clinical trials. Relevance to Patient Care and Clinical Practice: Erenumab is the first medication approved in the United States for the prevention of migraines in adults. No head-to-head data are available, but existing data suggest that erenumab is at least as effective as current off-label products and with reduced adverse effects. Conclusion: Erenumab is an effective once-monthly injectable agent for migraine prevention in patients with chronic or episodic migraine. It is also effective for patients who have previously failed migraine preventive therapy. Erenumab has a favorable adverse effect profile, which may improve patient adherence.
引用
收藏
页码：933 / 939
页数：7
相关论文
共 30 条
[1]  
[Anonymous], 2018, AIMOVIG
[2]   Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study [J].
Ashina, Messoud ;
Tepper, Stewart ;
Brandes, Jan Lewis ;
Reuter, Uwe ;
Boudreau, Guy ;
Dolezil, David ;
Cheng, Sunfa ;
Zhang, Feng ;
Lenz, Robert ;
Klatt, Jan ;
Mikol, Daniel D. .
CEPHALALGIA, 2018, 38 (10) :1611-1621
[3]   The International Classification of Headache Disorders, 3rd edition (beta version) [J].
Bes, Andre ;
Kunkel, Robert ;
Lance, James W. ;
Nappi, Giuseppe ;
Pfaffenrath, Volker ;
Rose, Frank Clifford ;
Schoenberg, Bruce S. ;
Soyka, Dieter ;
Tfelt-Hansen, Peer ;
Welch, K. Michael A. ;
Wilkinson, Marica ;
Olesen, Jes ;
Bousser, Marie-Germaine ;
Diener, Hans-Christoph ;
Dodick, David ;
First, Michael ;
Goadsby, Peter J. ;
Goebel, Hartmut ;
Lainez, Miguel J. A. ;
Lance, James W. ;
Lipton, Richard B. ;
Nappi, Giuseppe ;
Sakai, Fumihiko ;
Schoenen, Jean ;
Silberstein, Stephen D. ;
Steiner, Timothy J. ;
Olesen, Jes ;
Bendtsen, Lars ;
Dodick, David ;
Ducros, Anne ;
Evers, Stefan ;
First, Michael ;
Goadsby, Peter J. ;
Hershey, Andrew ;
Katsarava, Zaza ;
Levin, Morris ;
Pascual, Julio ;
Russell, Michael B. ;
Schwedt, Todd ;
Steiner, Timothy J. ;
Tassorelli, Cristina ;
Terwindt, Gisela M. ;
Vincent, Maurice ;
Wang, Shuu-Jiun ;
Olesen, J. ;
Evers, S. ;
Charles, A. ;
Hershey, A. ;
Lipton, R. ;
First, M. .
CEPHALALGIA, 2013, 33 (09) :629-808
[4]   The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies [J].
Burch, Rebecca ;
Rizzoli, Paul ;
Loder, Elizabeth .
HEADACHE, 2018, 58 (04) :496-505
[5]   Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab [J].
Buse, Dawn C. ;
Lipton, Richard B. ;
Hallstrom, Yngve ;
Reuter, Uwe ;
Tepper, Stewart J. ;
Zhang, Feng ;
Sapra, Sandhya ;
Picard, Hernan ;
Mikol, Daniel D. ;
Lenz, Robert A. .
CEPHALALGIA, 2018, 38 (10) :1622-1631
[6]   Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials [J].
Bussone, G ;
Diener, HC ;
Pfeil, J ;
Schwalen, S .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2005, 59 (08) :961-968
[7]   Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers [J].
de Hoon, Jan ;
van Hecken, Anne ;
Vandermeulen, Corinne ;
Herbots, Marissa ;
Kubo, Yumi ;
Lee, Ed ;
Eisele, Osa ;
Vargas, Gabriel ;
Gabriel, Kristin .
CEPHALALGIA, 2019, 39 (01) :100-110
[8]   A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina [J].
Depre, Christophe ;
Antalik, Lubomir ;
Starling, Amaal ;
Koren, Michael ;
Eisele, Osaro ;
Lenz, Robert A. ;
Mikol, Daniel D. .
HEADACHE, 2018, 58 (05) :715-723
[9]   Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study [J].
Diener, H-C ;
Bussone, G. ;
Van Oene, J. C. ;
Lahaye, M. ;
Schwalen, S. ;
Goadsby, P. J. .
CEPHALALGIA, 2007, 27 (07) :814-823
[10]   Topiramate in migraine prophylaxis -: Results from a placebo-controlled trial with propranolol as an active control [J].
Diener, HC ;
Tfelt-Hansen, P ;
Dahlöf, C ;
Láinez, MJA ;
Sandrini, G ;
Wang, SJ ;
Neto, W ;
Vijapurkar, U ;
Doyle, A ;
Jacobs, D .
JOURNAL OF NEUROLOGY, 2004, 251 (08) :943-950
123